). But there are plenty of other companies, including startups, that are trying to get a piece of the weight-loss market.
And when we think about the stats in the market, 40% of Americans today are obese, the expected global market for obesity drugs by 2030 is is expected to grow to $100 billion.The science is moving in a direction that's opening up opportunities to actually make a market impact for these patients that by the way have comorbidities like uh diabetes and other heart issues.
No, I think, you know, you've got to look at the dry powder that's been accumulating here in the past couple of years.So record levels of LP money going into biotech directed venture funds, uh over 25 billion just last year into fresh powder.Um that will be a uh an array of companies that go well beyond obesity, things that we see really getting a lot of focus and attention with dynamic science happening.We're seeing a lot of good companies um in, in that space.
Remember the lifeblood of a of a new drug starts uh on the bench at a university um several years prior to it becoming a drug. Um You've got other companies like Recursion Pharma out in Salt Lake City that's applying uh tech bio and A I to identifying drugs in both neural and oncology.